Covidien (COV) Tops Q3 EPS by 6c
Tweet
Share
E-mailGet Alerts COV Hot Sheet
Join SI Premium – FREE
Covidien (NYSE: COV) reported Q3 EPS of $1.01, $0.06 better than the analyst estimate of $0.95. Revenue for the quarter came in at $2.93 billion versus the consensus estimate of $2.86 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
